Investigational drug · Phase 3
SG001
Also called: enlonstobart, Enlonstobart will be administrated on a 14-day cycle
Not approved by FDA. In 15 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
15
15 still active
All registered trials
19
Any phase or sponsor naming "SG001"
First trial start
2023
Dec 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SG001", any sponsor or status.
- Phase 213
Conditions studied
As listed on its trial records.
- HER2-positive Gastric Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma
- Ovarian Cancer
- Recurrent Ovarian Cancer
- Non-Small Cell Lung Cancer
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Advanced Solid Tumors
- Advanced Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SG001" as an intervention, largest first.
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Pivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07251062 · 737 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2029
Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU); Investigator's choice of SOC and 1 more · For: Esophageal Squamous Cell Carcinoma
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07672223 · 586 participants (planned) · Start Jul 30, 2026 · Primary completion Sep 30, 2029
Drug: SYS6010; Enlonstobart and 5 more · For: Non-small Cell Lung Cancer
Sites: Shanghai, China · 2 sites in all
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07924111 · 585 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2029
Drug: SYS6010; SG001 and 2 more · For: Esophageal Squamous Cell Carcinoma
- SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Pivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07633873 · 500 participants (planned) · Start Jun 2, 2026 · Primary completion Sep 30, 2027
Drug: SYS6010 injection; Enlonstobart injection and 2 more · For: Non-Small Cell Lung Cancer
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT06989671 · 430 participants (planned) · Start Aug 30, 2025 · Primary completion Dec 30, 2027
Drug: JMT101; SYS6002 and 1 more · For: Head and Neck Squamous Cell Carcinoma
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Chest HospitalAcademic, hospital or other
NCT07662811 · 396 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 31, 2027
Drug: SYHX2011; Carboplatin and 4 more · For: Non-Small Cell Lung Cancer
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Pivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06682611 · 380 participants (planned) · Start Nov 13, 2024 · Primary completion Nov 13, 2026
Drug: SYHA1813; SG001 and 7 more · For: Unresectable Locally Advanced or Metastatic Solid Tumors
- Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)Pivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05715840 · 368 participants (planned) · Start Jan 31, 2023 · Primary completion Jul 31, 2024
Drug: SG001 injection; Paclitaxel and 4 more · For: Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT03852823 · 192 participants (planned) · Start May 23, 2019 · Primary completion Sep 2022
Drug: SG001 · For: Advanced Solid Tumours; Cervical Cancer; Malignant Mesothelioma and 2 more
Sites: Shanghai, China
- A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06132217 · 168 participants (planned) · Start Jan 30, 2024 · Primary completion Jan 30, 2027
Drug: Simmitinib; SG001 · For: Advanced Solid Tumor
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- The Comparative Effectiveness of Enlonstobart and Camrelizumab as Second-Line Recurrent or Metastatic Cervical Cancer Therapies: Matching-Adjusted and Simulated Treatment Comparisons.
Gu H, Hu B, Jiang Y · Immunotargets Ther 2026
- Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.
Fang J, Jiang O, Li W, et al. · Drug Des Devel Ther 2025
- Enlonstobart: First Approval.
Shirley M · Drugs 2024
- Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Li G, Li X, Yin R, et al. · Gynecol Oncol 2024
- Oryza glumaepatula and calcium oxide nanoparticles enhanced Cr stress tolerance by maintaining antioxidant defense, chlorophyll and gene expression levels in rice.
Ashraf H, Ghouri F, Zhong M, et al. · J Environ Manage 2024
- Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.
Zuo J, Duan W, Zhao M, et al. · Cancer Commun (Lond) 2024
Also in development for HER2-positive Gastric Cancer
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- HLX22Phase 34 trials
Shanghai Henlius Biotech · HER2 + Breast Cancer, HER2-low Hormone Receptor Positive Breast Cancer, Gastroesophageal-junction Cancer
- PembolizumabpembroPhase 33 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.